Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06978725 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

Study acronym: BEACON
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 2026 → Dec 31, 2028
Primary endpoint reworded 1 of 2 changed
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from Priovant Therapeutics, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Study title shortened, about 2 words
    v3
  2. Primary completion pushed from Dec 2026 to Dec 31, 2028v2 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Phase changed: Phase 2 → Phase 2/3
    • Enrollment increased: 28 → 168 participants
    • Study completion pushed from Dec 2026 to Dec 31, 2029
    • Trial arms changed: 3 → 5
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: 1 to 2
    • Study title shortened, about 6 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Trial Details
NCT Number NCT06978725
Lead Sponsor Priovant Therapeutics, Inc.
Conditions
(from sponsor)		 Cutaneous Sarcoidosis
Related terms Sarcoidosis
Enrollment 168 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov